Member area login
You don't have or don't remember the password!
Click Here
Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

--------------------

ISSN print: 0393 – 0564
ISSN digital: 0392- 7091



BC: Articoli scritti da C. Trevisiol

Raccomandazioni per l'implementazione del Test genetico BRCA1/2 nelle pazienti con carcinoma ovarico: dall'analisi sul tessuto tumorale a quella su DNA germinale.
Recommendations for the implementation of BRCA1/2testing in ovarian cancer patients: from tumor togermline analysis. Joint document from SIBioC, AIOM, SIGU, SIAPEC-IAP
<p>Since the approval of the first polyadenosine diphosphate (ADP) ribose polymerase inhibitor (PARPi), olaparib for platinum-sensitive relapsed highgrade ovarian cancer, with either germline or somatic BRCA1/2deleterious variants, the strategies for BRCA1/2testing are dynamically changing. In fact, along with germline assay, patients are now tested for tumor BRCA1/2alsoabove all for treatment decisions. In fact, it is reported as by tumor BRCA analysis we can identify 3&ndash;9% moremutated women which can therefore benefit from PARPi therapy. Although this new type of approach looks likechallenging, in particular due to the technical and analytical difficulties regarding low quality DNA deriving fromformalin-fixed paraffin-embedded specimens, the new CE-IVD on NGS-based pipelines, can overcome these issues,allowing specialized molecular laboratories to ensure high quality results and perform the best test settings.Nevertheless, each new NGS pipeline (CE-IVD or in house) should be validated using peculiar samples along withcommercially available reference and certified materials, before being introduced in routine settings. The validationset should be appropriately chosen in order to provide unequivocal data regarding robustness of each NGStBRCApipeline. Therefore, in order to harmonize the patient and laboratory path, a group of Italian Scientific Societies[Italian Society of Clinical Chemistry (SIBioC), Italian Association of Medical Oncology (AIOM), Italian Association ofClinical Pathology (SIAPEC), Italian Society of Human Genetics (SIGU)] provided the present recommendationswhich are aimed to guide all professionals (oncologists, gynaecologists, clinical and laboratory geneticists, clinicalmolecular biologists and pathologists). The intersociety group is confident that the present paper can offer all ovariancancer women a well-organized pathway of diagnosis and treatment.</p>
Biochimica Clinica ; 43(3) 332-338
Documenti SIBioC - SIBioC Documents
 
Guida all’uso clinico dei biomarcatori in oncologia: le prospettive
Guidelines for clinical use of biomarkers in oncology: an outlook
<p>Although much information has recently been accumulated in the field of biomarkers, no new markers have been approved by the U.S. Food and Drug Administration for clinical use over the last two decades. This fact emphasizes the need to strengthen translational research in order to select, evaluate, and validate the most promising biomarkers in a reliable and efficient manner. The most innovative development regarding traditional markers is in their dynamic assessment in the diagnostic scenario. This approach is under evaluation for several biomarkers, e.g. PSA for prostate cancer and CA 125 for ovarian cancer. On the other hand, new biomarkers are under study. Some promising biomarkers, such as the antibody immune response indicators, mechanism and/or microenvironment associated markers, and circulating tumour cells, are already in the validation phase. Even if they have preliminarily demonstrated very high potential, there is however insufficient evidence to support their definitive clinical use.</p>
Biochimica Clinica ; 36(1) 40-45
Documenti - Documents
 
Guida all'uso clinico dei biomarcatori in oncologia: i marcatori nelle diverse neoplasie - Parte II
Guidelines for clinical use of biomarkers of different neoplastic diseases - Part II.
<p><strong>Guidelines for clinical use of biomarkers of different neoplastic diseases &#8211; Part II.</strong> This contribution represents the second of two parts of guidelines for clinical use of tumour biomarkers, reporting in schematic tables the evidencebased information available for different neoplastic pathologies (the first part was published on Biochim Clin 2011;35:394-403). Particularly, the following neoplastic conditions are considered in this document: testicular seminoma and non-seminoma, cervical uterine cancer, ovarian and renal cell carcinomas, breast cancer, melanoma, and neuroendocrine tumors.</p>
Biochimica Clinica ; 35(6) 465-473
DOCUMENTI - DOCUMENTI
 
Guida all'uso clinico dei biomarcatori in oncologia: i marcatori nelle diverse neoplasie - Parte I
Guidelines for clinical use of biomarkers in different neoplastic diseases - Part I.
Biochimica Clinica ; 35(5) 394
DOCUMENTI - DOCUMENTI
 
Guida all'uso clinico dei biomarcatori in oncologia: metodologia e chiave di lettura
Guidelines for clinical use of biomarkers in oncology: methodology and reading key
Biochimica Clinica ; 35(4) 307
DOCUMENTI - DOCUMENTI
 
Guida all'uso clinico dei biomarcatori in oncologia: metodi di misura e interpretazione
Guidelines for clinical use of biomarkers in oncology: methods and interpretation
Biochimica Clinica ; 35(3) 199
DOCUMENTI - DOCUMENTI